{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:29:54Z","timestamp":1786375794247,"version":"build-2736575974"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH067924"],"award-info":[{"award-number":["R01MH067924"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH124705"],"award-info":[{"award-number":["R01MH124705"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","award":["Narsad Young Investigator Award"],"award-info":[{"award-number":["Narsad Young Investigator Award"]}],"id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000945","name":"Pittsburgh Foundation","doi-asserted-by":"publisher","award":["Rising Star Award"],"award-info":[{"award-number":["Rising Star Award"]}],"id":[{"id":"10.13039\/100000945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"DOI":"10.1038\/s41386-026-02522-y","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:15:49Z","timestamp":1786367749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["7T magnetic resonance spectroscopic imaging of subcortical neurometabolites across antipsychotic treatment in acutely symptomatic early-phase schizophrenia spectrum disorders"],"prefix":"10.1038","author":[{"given":"Michael","family":"Pupi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Papale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8092-3942","authenticated-orcid":false,"given":"Finnegan J.","family":"Calabro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Raminfard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Blazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tate","family":"Overbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-9798","authenticated-orcid":false,"given":"William","family":"Foran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoby P.","family":"Hetherington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan H.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5842-6782","authenticated-orcid":false,"given":"Deepak K.","family":"Sarpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"2522_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","volume":"77","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-an overview. JAMA Psychiatry. 2020;77:201\u201310.","journal-title":"JAMA Psychiatry"},{"key":"2522_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","volume":"399","author":"S Jauhar","year":"2022","unstructured":"Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399:473\u201386.","journal-title":"Lancet"},{"key":"2522_CR3","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","volume":"28","author":"M Solmi","year":"2023","unstructured":"Solmi M, Seitidis G, Mavridis D, Correll CU, Dragioti E, Guimond S, et al. Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Mol Psychiatry. 2023;28:5319\u201327.","journal-title":"Mol Psychiatry"},{"key":"2522_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/npp.2011.181","volume":"37","author":"B Moghaddam","year":"2012","unstructured":"Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implications for treatment. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2012;37:4\u201315.","journal-title":"Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol"},{"key":"2522_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/schbul\/sbr069","volume":"39","author":"A Marsman","year":"2013","unstructured":"Marsman A, van den Heuvel MP, Klomp DWJ, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull. 2013;39:120\u20139.","journal-title":"Schizophr Bull"},{"key":"2522_CR6","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/schbul\/sbs092","volume":"39","author":"LM Rowland","year":"2013","unstructured":"Rowland LM, Kontson K, West J, Edden RA, Zhu H, Wijtenburg SA, et al. In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull. 2013;39:1096\u2013104.","journal-title":"Schizophr Bull"},{"key":"2522_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41582-023-00904-0","volume":"20","author":"OD Howes","year":"2024","unstructured":"Howes OD, Bukala BR, Beck K. Schizophrenia: from neurochemistry to circuits, symptoms and treatments. Nat Rev Neurol. 2024;20:22\u201335.","journal-title":"Nat Rev Neurol"},{"key":"2522_CR8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","volume":"374","author":"J Tiihonen","year":"2009","unstructured":"Tiihonen J, L\u00f6nnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374:620\u20137.","journal-title":"Lancet"},{"key":"2522_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamapsychiatry.2018.0623","volume":"75","author":"CU Correll","year":"2018","unstructured":"Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M, et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry. 2018;75:555\u201365.","journal-title":"JAMA Psychiatry"},{"key":"2522_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106078","volume":"176","author":"A de Bartolomeis","year":"2022","unstructured":"de Bartolomeis A, Barone A, Begni V, Riva MA. Present and future antipsychotic drugs: a systematic review of the putative mechanisms of action for efficacy and a critical appraisal under a translational perspective. Pharm Res. 2022;176:106078.","journal-title":"Pharm Res"},{"key":"2522_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wps.20693","volume":"19","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19:15\u201333.","journal-title":"World Psychiatry"},{"key":"2522_CR12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951\u201362.","journal-title":"Lancet"},{"key":"2522_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","volume":"56","author":"D Robinson","year":"1999","unstructured":"Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"2522_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1192\/bjp.2021.61","volume":"220","author":"D Siskind","year":"2022","unstructured":"Siskind D, Orr S, Sinha S, Yu O, Brijball B, Warren N, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. 2022;220:115\u201320.","journal-title":"Br J Psychiatry"},{"key":"2522_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/nedt.2006.2.4.531","volume":"2","author":"CR Bowie","year":"2006","unstructured":"Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat. 2006;2:531\u20136.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2522_CR16","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/npp.2011.65","volume":"36","author":"Cdela Fuente-Sandoval","year":"2011","unstructured":"Fuente-Sandoval Cdela, Le\u00f3n-Ortiz P, Favila R, Stephano S, Mamo D, Ram\u00edrez-Berm\u00fadez J, et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology. 2011;36:1781\u201391.","journal-title":"Neuropsychopharmacology"},{"key":"2522_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","volume":"73","author":"K Merritt","year":"2016","unstructured":"Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK. Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies. JAMA Psychiatry. 2016;73:665\u201374.","journal-title":"JAMA Psychiatry"},{"key":"2522_CR18","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41380-018-0082-9","volume":"23","author":"A Egerton","year":"2018","unstructured":"Egerton A, Broberg BV, Van Haren N, Merritt K, Barker GJ, Lythgoe DJ, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE). Mol Psychiatry. 2018;23:2145\u201355.","journal-title":"Mol Psychiatry"},{"key":"2522_CR19","first-page":"703","volume":"9","author":"KB Bojesen","year":"2024","unstructured":"Bojesen KB, Rostrup E, Sigvard AK, Mikkelsen M, Edden RAE, Ebdrup BH, et al. The trajectory of prefrontal GABA levels in initially antipsychotic-na\u00efve patients with psychosis during 2 years of treatment and associations with striatal cerebral blood flow and outcome. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9:703\u201313.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"2522_CR20","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1038\/s41380-025-03234-3","volume":"30","author":"KB Bojesen","year":"2025","unstructured":"Bojesen KB, Lemvigh CK, Sigvard AK, Vestergaard MB, Larsson HBW, Rostrup E, et al. Cerebral glutamate levels over two years in initially antipsychotic-na\u00efve first-episode patients with psychosis are related to clinical symptoms and cognition. Mol Psychiatry. 2025;30:5652\u201363.","journal-title":"Mol Psychiatry"},{"key":"2522_CR21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1017\/S1461145712000314","volume":"16","author":"C de la Fuente-Sandoval","year":"2013","unstructured":"de la Fuente-Sandoval C, Le\u00f3n-Ortiz P, Azc\u00e1rraga M, Favila R, Stephano S, Graff-Guerrero A. Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. Int J Neuropsychopharmacol. 2013;16:471\u20135.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2522_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1001\/jamapsychiatry.2014.1734","volume":"72","author":"DK Sarpal","year":"2015","unstructured":"Sarpal DK, Robinson DG, Lencz T, Argyelan M, Ikuta T, Karlsgodt K, et al. Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia. JAMA Psychiatry. 2015;72:5\u201313.","journal-title":"JAMA Psychiatry"},{"key":"2522_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2018.06.021","volume":"131","author":"G Tarcijonas","year":"2019","unstructured":"Tarcijonas G, Sarpal DK. Neuroimaging markers of antipsychotic treatment response in schizophrenia: an overview of magnetic resonance imaging studies. Neurobiol Dis. 2019;131:104209.","journal-title":"Neurobiol Dis"},{"key":"2522_CR24","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41380-025-03229-0","volume":"31","author":"KB Bojesen","year":"2026","unstructured":"Bojesen KB, Ambrosen KS, Sigvard AK, Nielsen M\u00d8, Gjedde A, Kumakura Y, et al. Interrelations between dopaminergic-, GABAergic- and glutamatergic neurotransmitters in antipsychotic-na\u00efve psychosis patients and the association to initial treatment response. Mol Psychiatry. 2026;31:1231\u201340.","journal-title":"Mol Psychiatry"},{"key":"2522_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41386-024-01980-6","volume":"50","author":"FJ Calabro","year":"2024","unstructured":"Calabro FJ, Parr AC, Sydnor VJ, Hetherington H, Prasad KM, Ibrahim TS, et al. Leveraging ultra-high field (7T) MRI in psychiatric research. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2024;50:85\u2013102.","journal-title":"Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol"},{"key":"2522_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s11064-018-2521-z","volume":"44","author":"JMN Duarte","year":"2019","unstructured":"Duarte JMN, Xin L. Magnetic resonance spectroscopy in schizophrenia: evidence for glutamatergic dysfunction and impaired energy metabolism. Neurochem Res. 2019;44:102\u201316.","journal-title":"Neurochem Res"},{"key":"2522_CR27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41380-021-01297-6","volume":"27","author":"T Nakahara","year":"2022","unstructured":"Nakahara T, Tsugawa S, Noda Y, Ueno F, Honda S, Kinjo M, et al. Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies. Mol Psychiatry. 2022;27:744\u201357.","journal-title":"Mol Psychiatry"},{"key":"2522_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.schres.2022.08.008","volume":"248","author":"SF Sonnenschein","year":"2022","unstructured":"Sonnenschein SF, Mayeli A, Yushmanov VE, Blazer A, Calabro FJ, Perica M, et al. A longitudinal investigation of GABA, glutamate, and glutamine across the insula during antipsychotic treatment of first-episode schizophrenia. Schizophr Res. 2022;248:98\u2013106.","journal-title":"Schizophr Res"},{"key":"2522_CR29","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1093\/cercor\/bht165","volume":"24","author":"A Anticevic","year":"2014","unstructured":"Anticevic A, Cole MW, Repovs G, Murray JD, Brumbaugh MS, Winkler AM, et al. Characterizing thalamo-cortical disturbances in schizophrenia and bipolar illness. Cereb Cortex. 2014;24:3116\u201330.","journal-title":"Cereb Cortex"},{"key":"2522_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1503\/jpn.100176","volume":"37","author":"L Palaniyappan","year":"2012","unstructured":"Palaniyappan L, Liddle PF. Does the salience network play a cardinal role in psychosis? An emerging hypothesis of insular dysfunction. J Psychiatry Neurosci JPN. 2012;37:17\u201327.","journal-title":"J Psychiatry Neurosci JPN"},{"key":"2522_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/schbul\/sbx190","volume":"45","author":"MA Reid","year":"2019","unstructured":"Reid MA, Salibi N, White DM, Gawne TJ, Denney TS, Lahti AC. 7T proton magnetic resonance spectroscopy of the anterior cingulate cortex in first-episode schizophrenia. Schizophr Bull. 2019;45:180\u20139.","journal-title":"Schizophr Bull"},{"key":"2522_CR32","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1038\/s41380-023-01969-5","volume":"28","author":"M Wang","year":"2023","unstructured":"Wang M, Barker PB, Cascella NG, Coughlin JM, Nestadt G, Nucifora FC, et al. Longitudinal changes in brain metabolites in healthy controls and patients with first episode psychosis: a 7-Tesla MRS study. Mol Psychiatry. 2023;28:2018\u201329.","journal-title":"Mol Psychiatry"},{"key":"2522_CR33","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41380-020-0704-x","volume":"25","author":"K Dempster","year":"2020","unstructured":"Dempster K, Jeon P, MacKinley M, Williamson P, Th\u00e9berge J, Palaniyappan L. Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate. Mol Psychiatry. 2020;25:1640\u201350.","journal-title":"Mol Psychiatry"},{"key":"2522_CR34","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/s41386-020-00920-4","volume":"46","author":"GM Qui\u00f1ones","year":"2021","unstructured":"Qui\u00f1ones GM, Mayeli A, Yushmanov VE, Hetherington HP, Ferrarelli F. Reduced GABA\/glutamate in the thalamus of individuals at clinical high risk for psychosis. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2021;46:1133\u20139.","journal-title":"Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol"},{"key":"2522_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-73322-x","volume":"14","author":"D Andreou","year":"2024","unstructured":"Andreou D, J\u00f8rgensen KN, Nerland S, Calkova T, M\u00f8rch-Johnsen L, Smelror RE, et al. Caudate nucleus volume in medicated and unmedicated patients with early- and adult-onset schizophrenia. Sci Rep. 2024;14:22755.","journal-title":"Sci Rep"},{"key":"2522_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1001\/archpsyc.62.4.371","volume":"62","author":"J Hirvonen","year":"2005","unstructured":"Hirvonen J, van Erp TGM, Huttunen J, Aalto S, N\u00e5gren K, Huttunen M, et al. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry. 2005;62:371\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"2522_CR37","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/jamapsychiatry.2013.289","volume":"70","author":"C de la Fuente-Sandoval","year":"2013","unstructured":"de la Fuente-Sandoval C, Le\u00f3n-Ortiz P, Azcarraga M, Stephano S, Favila R, D\u00edaz-Galvis L, et al. Glutamate Levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis. JAMA Psychiatry Chic Ill. 2013;70:1057\u201366.","journal-title":"JAMA Psychiatry Chic Ill"},{"key":"2522_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2022.102370","volume":"219","author":"MI Perica","year":"2022","unstructured":"Perica MI, Calabro FJ, Larsen B, Foran W, Yushmanov VE, Hetherington H, et al. Development of frontal GABA and glutamate supports excitation\/inhibition balance from adolescence into adulthood. Prog Neurobiol. 2022;219:102370.","journal-title":"Prog Neurobiol"},{"key":"2522_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41537-018-0063-7","volume":"4","author":"R Newton","year":"2018","unstructured":"Newton R, Rouleau A, Nylander A-G, Loze J-Y, Resemann HK, Steeves S, et al. Diverse definitions of the early course of schizophrenia\u2014a targeted literature review. NPJ Schizophr. 2018;4:21.","journal-title":"NPJ Schizophr"},{"key":"2522_CR40","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1751-7893.2009.00148.x","volume":"3","author":"NJK Breitborde","year":"2009","unstructured":"Breitborde NJK, Srihari VH, Woods SW. Review of the operational definition for first-episode psychosis. eip Early Inter Psychiatry. 2009;3:259\u201365.","journal-title":"eip Early Inter Psychiatry"},{"key":"2522_CR41","first-page":"112","volume":"24","author":"MG Woerner","year":"1988","unstructured":"Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull. 1988;24:112\u20137.","journal-title":"Psychopharmacol Bull"},{"key":"2522_CR42","unstructured":"First MB. Structured clinical interview for the DSM (SCID). Encycl Clin Psychol. Chichester, West Sussex, UK: John Wiley & Sons, Ltd; 2015. p. 1\u20136."},{"key":"2522_CR43","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen NC, Carpenter WT Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441\u20139.","journal-title":"Am J Psychiatry"},{"key":"2522_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1600-0447.2005.00659.x","volume":"113","author":"J van Os","year":"2006","unstructured":"van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand. 2006;113:91\u201395.","journal-title":"Acta Psychiatr Scand"},{"key":"2522_CR45","doi-asserted-by":"crossref","unstructured":"Leucht S, Davis JM, Engel RR, Kissling W, Kane JM Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl. 2009;438:7\u201314.","DOI":"10.1111\/j.1600-0447.2008.01308.x"},{"key":"2522_CR46","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.neuroimage.2009.10.002","volume":"49","author":"JP Marques","year":"2010","unstructured":"Marques JP, Kober T, Krueger G, van der Zwaag W, Van de Moortele P-F, Gruetter R. MP2RAGE, a self-bias-field corrected sequence for improved segmentation and T1-mapping at high field. NeuroImage. 2010;49:1271\u201381.","journal-title":"NeuroImage"},{"key":"2522_CR47","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/nbm.698","volume":"14","author":"SW Provencher","year":"2001","unstructured":"Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14:260\u20134.","journal-title":"NMR Biomed"},{"key":"2522_CR48","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/jmri.23945","volume":"37","author":"S Posse","year":"2013","unstructured":"Posse S, Otazo R, Dager SR, Alger J. MR spectroscopic imaging: principles and recent advances. J Magn Reson Imaging JMRI. 2013;37:1301\u201325.","journal-title":"J Magn Reson Imaging JMRI"},{"key":"2522_CR49","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41380-024-02860-7","volume":"30","author":"AC Parr","year":"2025","unstructured":"Parr AC, Perica MI, Calabro FJ, Foran W, Moon CH, Hetherington H, et al. Adolescent maturation of dorsolateral prefrontal cortex glutamate: GABA and cognitive function is supported by dopamine-related neurobiology. Mol Psychiatry. 2025;30:2558\u201372.","journal-title":"Mol Psychiatry"},{"key":"2522_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.4484","volume":"34","author":"A Lin","year":"2021","unstructured":"Lin A, Andronesi O, Bogner W, Choi I-Y, Coello E, Cudalbu C, et al. Minimum reporting standards for in vivo magnetic resonance spectroscopy (MRSinMRS): experts\u2019 consensus recommendations. NMR Biomed. 2021;34:e4484.","journal-title":"NMR Biomed"},{"key":"2522_CR51","unstructured":"Team RC R: A language and environment for statistical computing, R Foundation for Statistical Computing. 2020."},{"key":"2522_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67:1\u201348.","journal-title":"J Stat Softw"},{"key":"2522_CR53","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57:289\u2013300.","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"2522_CR54","doi-asserted-by":"publisher","first-page":"e0121945","DOI":"10.1371\/journal.pone.0121945","volume":"10","author":"B Diedenhofen","year":"2015","unstructured":"Diedenhofen B, Musch J. Cocor: a comprehensive solution for the statistical comparison of correlations. PLOS ONE. 2015;10:e0121945.","journal-title":"PLOS ONE"},{"key":"2522_CR55","doi-asserted-by":"publisher","unstructured":"Woodward ND, Karbasforoushan H, Heckers S. Thalamocortical dysconnectivity in schizophrenia. Am J Psychiatry. 2012;169: https:\/\/doi.org\/10.1176\/appi.ajp.2012.12010056.","DOI":"10.1176\/appi.ajp.2012.12010056"},{"key":"2522_CR56","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jnc.15811","volume":"166","author":"JV Andersen","year":"2023","unstructured":"Andersen JV, Schousboe A. Milestone review: metabolic dynamics of glutamate and GABA mediated neurotransmission\u2014the essential roles of astrocytes. J Neurochem. 2023;166:109\u201337.","journal-title":"J Neurochem"},{"key":"2522_CR57","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1471-4159.2011.07338.x","volume":"118","author":"JH Neale","year":"2011","unstructured":"Neale JH, Olszewski RT, Zuo D, Janczura KJ, Profaci CP, Lavin KM, et al. Advances in understanding the peptide neurotransmitter NAAG and the appearance of a new member of the NAAG neuropeptide family. J Neurochem. 2011;118:490\u20138.","journal-title":"J Neurochem"},{"key":"2522_CR58","first-page":"833","volume":"11","author":"M Mezler","year":"2010","unstructured":"Mezler M, Geneste H, Gault L, Marek G. LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs Lond Engl. 2010;11:833\u201345.","journal-title":"Curr Opin Investig Drugs Lond Engl"},{"key":"2522_CR59","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1471-4159.2011.07380.x","volume":"119","author":"JH Neale","year":"2011","unstructured":"Neale JH. N-acetylaspartylglutamate is an agonist at mGluR\u2083 in vivo and in vitro. J Neurochem. 2011;119:891\u20135.","journal-title":"J Neurochem"},{"key":"2522_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1385\/JMN:26:1:001","volume":"26","author":"MH Baslow","year":"2005","unstructured":"Baslow MH, Dyakin VV, Nowak KL, Hungund BL, Guilfoyle DN. 2-PMPA, a NAAG peptidase inhibitor, attenuates magnetic resonance BOLD signals in the brain of anesthetized mice. J Mol Neurosci. 2005;26:1\u201316.","journal-title":"J Mol Neurosci"},{"key":"2522_CR61","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1016\/j.neuron.2025.08.009","volume":"113","author":"BS Khakh","year":"2025","unstructured":"Khakh BS. On astrocyte-neuron interactions: broad insights from the striatum. Neuron. 2025;113:3079\u2013107.","journal-title":"Neuron"},{"key":"2522_CR62","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1038\/s42255-025-01404-9","volume":"7","author":"JP Bola\u00f1os","year":"2025","unstructured":"Bola\u00f1os JP, Magistretti PJ. The neuron\u2013astrocyte metabolic unit as a cornerstone of brain energy metabolism in health and disease. Nat Metab. 2025;7:2414\u201323.","journal-title":"Nat Metab"},{"key":"2522_CR63","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamapsychiatry.2025.4091","volume":"83","author":"LF Rivera-Ch\u00e1vez","year":"2026","unstructured":"Rivera-Ch\u00e1vez LF, Gonz\u00e1lez-Sangabriel D, Gonz\u00e1lez-Manr\u00edquez L, Moncada-Habib T, Le\u00f3n-Ortiz P, Malacara M, et al. Glutamate levels in medial prefrontal cortex according to illness phase of never-medicated individuals with psychosis. JAMA Psychiatry. 2026;83:404\u20138.","journal-title":"JAMA Psychiatry"},{"key":"2522_CR64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2213880120","volume":"120","author":"D Schijven","year":"2023","unstructured":"Schijven D, Postema MC, Fukunaga M, Matsumoto J, Miura K, de Zwarte SMC, et al. Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium. Proc Natl Acad Sci. 2023;120:e2213880120.","journal-title":"Proc Natl Acad Sci"},{"key":"2522_CR65","doi-asserted-by":"publisher","unstructured":"Chopra S, Worhunsky PD, Naganawa M, Zhang X-H, Segal A, Labache L, et al. Widespread synaptic density loss in schizophrenia follows molecular and network architecture. Mol Psychiatry. 2026:1\u201312. https:\/\/doi.org\/10.1038\/s41380-026-03717-x. online ahead of print.","DOI":"10.1038\/s41380-026-03717-x"},{"key":"2522_CR66","doi-asserted-by":"publisher","unstructured":"King B, Bojesen KB, Crisp C, de Bartolomeis A, de Haan L, de la Fuente-Sandoval C, et al. Neurometabolites and antipsychotic response in psychosis: a mega-analysis. JAMA Psychiatry. 2026:e261674. https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.1674. Online ahead of print.","DOI":"10.1001\/jamapsychiatry.2026.1674"},{"key":"2522_CR67","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.pscychresns.2008.06.002","volume":"172","author":"D Ong\u00fcr","year":"2009","unstructured":"Ong\u00fcr D, Prescot AP, Jensen JE, Cohen BM, Renshaw PF. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res. 2009;172:44\u201348.","journal-title":"Psychiatry Res"},{"key":"2522_CR68","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.neuroimage.2019.02.059","volume":"191","author":"M Mikkelsen","year":"2019","unstructured":"Mikkelsen M, Rimbault DL, Barker PB, Bhattacharyya PK, Brix MK, Buur PF, et al. Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites. NeuroImage. 2019;191:537\u201348.","journal-title":"NeuroImage"},{"key":"2522_CR69","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/mrm.24291","volume":"69","author":"PG Tibbo","year":"2013","unstructured":"Tibbo PG, Bernier D, Hanstock CC, Seres P, Lakusta B, Purdon SE. 3-T proton magnetic spectroscopy in unmedicated first episode psychosis: a focus on creatine. Magn Reson Med. 2013;69:613\u201320.","journal-title":"Magn Reson Med"},{"key":"2522_CR70","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/oxfordjournals.schbul.a007049","volume":"29","author":"SJ Wood","year":"2003","unstructured":"Wood SJ, Berger G, Velakoulis D, Phillips LJ, McGorry PD, Yung AR, et al. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr Bull. 2003;29:831\u201343.","journal-title":"Schizophr Bull"},{"key":"2522_CR71","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0920-9964(02)00210-4","volume":"58","author":"JR Bustillo","year":"2002","unstructured":"Bustillo JR, Lauriello J, Rowland LM, Thomson LM, Petropoulos H, Hammond R, et al. Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr Res. 2002;58:313\u201321.","journal-title":"Schizophr Res"},{"key":"2522_CR72","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/mrm.24352","volume":"69","author":"L Xin","year":"2013","unstructured":"Xin L, Schaller B, Mlynarik V, Lu H, Gruetter R. Proton T1 relaxation times of metabolites in human occipital white and gray matter at 7 T. Magn Reson Med. 2013;69:931\u20136.","journal-title":"Magn Reson Med"},{"key":"2522_CR73","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/mrm.20901","volume":"55","author":"C Gasparovic","year":"2006","unstructured":"Gasparovic C, Song T, Devier D, Bockholt HJ, Caprihan A, Mullins PG, et al. Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn Reson Med. 2006;55:1219\u201326.","journal-title":"Magn Reson Med"},{"key":"2522_CR74","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(13)62036-X","volume":"383","author":"OD Howes","year":"2014","unstructured":"Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;383:1677\u201387.","journal-title":"Lancet"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02522-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02522-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02522-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:02:10Z","timestamp":1786374130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02522-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":74,"alternative-id":["2522"],"URL":"https:\/\/doi.org\/10.1038\/s41386-026-02522-y","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}